CD4 and COVID-19: MIS-C is also unique in that it features an expansion of the expansion of polyclonal Vbeta21.3 T cells in both the CD4 and CD8 subsets not directed against antigenic peptides of SARS-CoV2, which was not detected in patients with KD, TSS and acute COVID-19 (see details later).